Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis.

Background & Aims: PEDFIC 2, an ongoing, open-label, 72-week study, evaluates odevixibat, an ileal bile acid transporter inhibitor, in patients with progressive familial intrahepatic cholestasis.
Methods: PEDFIC 2 enrolled and dosed 69 patients across two cohorts; all received odevixibat 120 μg/kg per day. Cohort 1 comprised children from PEDFIC 1, and cohort 2 comprised new patients (any age). We report data through 15 July 2020, with Week 24 of PEDFIC 2 the main time point analysed. This represents up to 48 weeks of cumulative exposure for patients treated with odevixibat from the 24-week PEDFIC 1 study (cohort 1A) and up to 24 weeks of treatment for those who initiated odevixibat in PEDFIC 2 (patients who received placebo in PEDFIC 1 [cohort 1B] or cohort 2 patients). Primary endpoints for this prespecified interim analysis were change from baseline to Weeks 22-24 in serum bile acids (sBAs) and proportion of positive pruritus assessments (≥1-point drop from PEDFIC 2 baseline in pruritus on a 0-4 scale or score ≤1) over the 24-week period. Safety monitoring included evaluating treatment-emergent adverse events (TEAEs).
Results: In cohort 1A, mean change from PEDFIC 1 baseline to Weeks 22-24 of PEDFIC 2 in sBAs was -201 μmol/L ( p <0.0001). For cohort 1B and cohort 2, mean changes from odevixibat initiation to weeks 22-24 in sBAs were -144 and -104 μmol/L, respectively. The proportion of positive pruritus assessments in the first 24-week period of PEDFIC 2 was 33%, 56%, and 62% in cohorts 1A, 1B, and 2, respectively. Most TEAEs were mild or moderate. No drug-related serious TEAEs occurred.
Conclusions: Odevixibat in patients with progressive familial intrahepatic cholestasis was generally well tolerated and associated with sustained reductions in sBAs and pruritus.
Clinical Trials Registration: This study is registered at ClinicalTrials.gov (NCT03659916).
Impact and Implications: Disrupted bile flow is a hallmark feature of patients with progressive familial intrahepatic cholestasis and can result in build-up of bile constituents in the liver with spill over into the bloodstream; other effects that patients can experience include extremely itchy skin, and because not enough bile reaches the gut, patients can have problems digesting food, which may lead to poor growth. Odevixibat is an orally administered medication that shunts bile acids away from the liver. The current study, called PEDFIC 2, suggested that odevixibat can improve the problematic signs and symptoms of progressive familial intrahepatic cholestasis and was generally safe for patients.
Competing Interests: RJT: Albireo and Mirum – Consultant; Generation Bio – Consultant and stock options; Rectify Therapeutics – Consultant and stockholder; LD: Albireo, Alexion, Mirum, Selecta, Vivet, Spark, Tome, and Genespire – Consultant; ADG: Albireo – Consultant; UB: Albireo, Mirum, Alnylam, Vivet, and Nestlé – Consultant; EG: Laboratoires C.T.R.S., Mirum, Vivet, and Albireo – Consultant; TG: Albireo – Consultant; RHJH: GMP-Orphan and Univar – Consultant; BMK: Albireo, Mirum, and Audentes – Consultant; Albireo and Mirum – Unrestricted educational grants; SJK: Albireo, HemoShear, Intercept, Mirum, and Vertex – Consultant; FL: Alexion – Consultant; AL: GMP-Orphan and CSL Behring – Consultant; EL: Mirum – Received honoraria; KML: Albireo, Mirum, and Travere Therapeutics – Consultant; CM: Albireo – Consultant; PM: Sobi AB and Albireo – Consultant; EtSo: Cellaion – Chairman and CEO; Albireo – Consultant and investigator; Mirum and Intercept – Investigator; RJS: Mirum, Albireo, and Alexion – Consultant; EkSt: Albireo and Mirum – Consultant and research support; Univar – Consultant; Orphalan – Speaker's fee; HJV: Ausnutria BV, Albireo, Danone/Nutricia Research, Intercept, Mirum, Orphalan, and Vivet – Consultant; JMV: Mirum – Consultant; JPM, QN, TW, NW, QY, PH, and LK: Albireo – current or former employment; RA, PLC, PC, BD, ÖD, GG, WH, HÖ, SRR, BR, EySh, NS, MET, and WLvdW: nothing to disclose. Please refer to the accompanying ICMJE disclosure forms for further details.
(© 2023 The Authors.)